LearnGlossaryMarketStocksSuperinvestorsSign in

ORIC

ORIC Pharmaceuticals, Inc.

Healthcare · $1.4B market cap

Verdict

We can't put a fair value on ORIC right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-20.5% a year✗
Sales growth—?
Free cash flow growth—?
Return on invested capital-46.5%✗

Follow ORIC

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds ORIC. In Q2 2026, 1 trimmed. Who we track

Viking Global Investors

Viking Global Investors · as of Q2 2026

$55.5M

5,126,762 shares

Moves in Q2 2026

Trimmed: Viking Global Investors

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works